Benefits for children with suspected cancer from routine whole-genome sequencing
Open Access
- 2 July 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1905-1912
Abstract
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.Keywords
Funding Information
- Wellcome Trust (220540/Z/20/A and 223135/Z/21/Z)
- NIHR Cambridge Biomedical Research Centre
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- The Pessoa de Araujo family - Personal Fellowship to Dr Angus Hodder
- DH | National Institute for Health Research
- NIHR GOSH Biomedical Research Centre
This publication has 50 references indexed in Scilit:
- Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgementeClinicalMedicine, 2023
- Recurrent FOSL1 rearrangements in desmoplastic fibroblastomaThe Journal of Pathology, 2023
- Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’European Journal of Cancer, 2022
- Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractorCell Genomics, 2022
- Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumoursNature, 2018
- Deregulation of DUX4 and ERG in acute lymphoblastic leukemiaNature Genetics, 2016
- Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot studyEuropean Journal of Cancer, 2016
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid TumorsJAMA Oncology, 2016
- Recurrent somatic mutations in regulatory regions of human cancer genomesNature Genetics, 2015
- Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor typesNature Genetics, 2014